Background
Vitiligo is an autoimmune disease characterised by acquired loss of melanocytes. Although the pathogenesis of vitiligo remains unknown, oxidative stress and autoimmune dysregulations are considered to play a role.
Objective
The aim of this study was to evaluate the HLA profile and total antioxidant capacity (TAC) and their relationship to clinical characteristic of vitiligo patients.
Methods
Ninety‐one vitiligo patients and 100 healthy controls were included in the study. We analysed HLA allele frequencies using sequence‐specific oligonucleotide Prob (SSOP) method. Serum total antioxidant capacity (TAC) levels were measured and compared between vitiligo patients and controls.
Results
HLA‐A*02 allele frequency was increased (OR = 1.6, CI = 1.12‐2.24, P = .009), HLA‐A*11 (OR = 0.46, CI = 0.32‐0.91, P = .019) and HLA‐DRB1*01 (OR = 0.39, CI = 0.16‐0.92, P = .029) frequencies were decreased in vitiligo patients. HLA‐A*02 allele especially increased the risk of late onset (Vitiligo onset >30 years of age) vitiligo (OR:3.67, 95% CI: 1.63‐8.26, P = .002). Serum TAC levels were similar between vitiligo patients and healthy controls but TAC levels were significantly lower in patients who did not have an HLA‐DRB1*01 allele (1.52 vs 1.61, P = .033).
Conclusion
Our study showed that HLA‐A*02 increases, HLA‐A*11 and HLA‐DRB1*01 decreases vitiligo susceptibility in Turkish patients as well as a possible relationship between HLA and TAC.